Customer Spotlight: Amgen on AbD and CLD
Find out how Amgen is transforming their antibody discovery and clonal cell line processes with the Berkeley Lights Platform.
Download FileRelated Resources
View All ResourcesWebinar: Accelerating Discovery and Development of Antibody Therapeutics
Hear from BLI experts Renee Tobias and Anupam Singhal about the unique benefits to leveraging a single platform for both the identification of promising candidates and the production of leading therapeutic molecules.
Webinar: Looking to the Future: What’s next in Antibody Therapeutics
At the 2021 AE&T EU conference, Tracey Mullens, CEO of Abveris, and Brian Walters, CEO of Genovac, joined John Proctor, SVP Antibody Therapeutics, for a discussion about the evolving landscape of antibody therapeutics, the technologies they have turned to address today’s complex targets, and how they are preparing for tomorrow’s challenges.
App Note: Discover Lead Molecules Against Difficult Targets in 1 Week with Opto™ Plasma B Discovery 4.0
Find out how the Opto Plasma B Discovery 4.0 workflow can be used to access broad plasma cell diversity, rapidly down-select lead candidates with functional profiling, and sequence and re-express >1,000 functionally characterized antibodies in 1 week.